论文部分内容阅读
对我国研制的伤寒Vi多糖菌苗进行接种反应及流行病学效果观察，并以其稀释液作为对照，对777名接种者的反应观察结果表明，菌苗组发热弱、中反应率分别为16．93％和0．05％，对照组分别为15．01％和0．03％．两者发热反应率无显著差异。菌苗组仅出现2例局部轻反应。对81506名接种者观察，以血培养伤寒杆菌阳性作为病人诊断标准，菌苗的保护指数为3．49，保护率为71．35％。临床资料显示，接种组发病者的发热强度明显低于对照组发病者。作者认为该苗全身、局部反应轻微，安全性好，保护率较高，发病者可降低发热强度，且初免只需注射一针，是一种值得推广使用的新一代菌苗。
Inoculation reaction and epidemiological observation of typhoid Vi polysaccharide vaccine developed in China were carried out. The dilution of the vaccine was used as a control. The response to 777 vaccinates showed that the vaccine group had weak fever and medium response rates of 16 .93% and 0.05% in the control group and 15.01% and 0.03% in the control group respectively. There was no significant difference in fever response rate between the two groups. Bacterial vaccine group showed only 2 cases of local light response. 81506 vaccination were observed, with blood cultures of typhoid bacillus positive as the diagnostic criteria of the patient, the protective index of the vaccine was 3.49, the protection rate was 71.35%. Clinical data show that the incidence of fever in vaccination group was significantly lower than those in the control group. The author believes that the whole body of the seedlings, local reaction is mild, good safety, high protection rate, the incidence of fever can reduce the intensity, and the initial injection just need a shot, is worth promoting the use of a new generation of vaccine.